Molecular Formula | C17H26N4O |
Molar Mass | 302.41 |
Density | 1.15±0.1 g/cm3(Predicted) |
Boling Point | 446.6±55.0 °C(Predicted) |
Flash Point | 223.9°C |
Vapor Presure | 3.59E-08mmHg at 25°C |
pKa | 8.86±0.10(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.594 |
In vitro study | Emedastine inhibits histamine H 2 receptor (K i =49067 nM) and histamine H 3 receptor (K i =12430 nM). High concentrations of Emedastine (1 and 10 ng/ml) significantly inhibits type 1 collagen production in normal human dermal fibroblasts. Emedastine (1, 10, 100, 1000 nM) at concentrations of ≥ 10 nM inhibits CC chemokine-elicited eosinophil migration. |
In vivo study | Emedastine (0.03, 0.1, 0.3 mg/kg; orally; pretreatment of 30 min) significantly suppresses histamine-induced scratching with 0.1 and 0.3 mg/kg but not 0.03 mg/kg. Pretreatment with Emedastine (0.03, 0.1, 0.3 mg/kg; orally) significantly inhibits the scratching induced by substance P and leukotriene B. Emedastine (0.3 mg/kg, p.o.) produces significant inhibition of passive peritoneal anaphylaxis in guinea-pigs. Emedastine inhibits histamine-induced contractions of isolated ileum (IC 50 =6.1 nM). Animal Model: Male ICR mice 5-6 weeks of age Dosage: 0.03, 0.1, 0.3 mg/kg Administration: Orally; 30 min before pruritogen injection Result: Significantly suppressed histamine-induced scratching with pretreatment of 0.1 and 0.3 mg/kg. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.307 ml | 16.534 ml | 33.068 ml |
5 mM | 0.661 ml | 3.307 ml | 6.614 ml |
10 mM | 0.331 ml | 1.653 ml | 3.307 ml |
5 mM | 0.066 ml | 0.331 ml | 0.661 ml |